# TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Source: https://onco.cc/trials/nct06532812/  
OnCo record `nct06532812` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of fludarabine, aldesleukin (high-dose il-2) and pembrolizumab in triple-negative breast cancer, run by Essen Biotech, now recruiting.

## Summary

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer is a phase 1/2, interventional study registered as NCT06532812 by Essen Biotech, with a registry enrolment figure of 85 participants, started 2024-08-22 and due to reach its primary completion in 2025-12-10. Interventions recorded: Tumor Infiltrating Lymphocytes (TIL); Cyclophosphamid; Fludarabine; Interleukin-2; Pembrolizumab. Conditions listed: Breast Cancer; Breast Carcinoma; Breast Cancer Metastatic; Breast Cancer Triple Negative. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: BAH249
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06532812
- Phase: 1/2
- Setting: Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab (Keytruda) Immunotherapy in Patients With Advanced or Metastatic Refractory Breast Cancer
- Sponsor: Essen Biotech
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT06532812: https://clinicaltrials.gov/study/NCT06532812

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Aldesleukin (high-dose IL-2)](https://onco.cc/drugs/aldesleukin/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06532812.json